Parnax Lab Ltd
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
- Market Cap ₹ 149 Cr.
- Current Price ₹ 130
- High / Low ₹ 182 / 96.2
- Stock P/E 162
- Book Value ₹ 20.4
- Dividend Yield 0.00 %
- ROCE 3.09 %
- ROE 4.00 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 32.1 to 23.1 days.
Cons
- Stock is trading at 6.38 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.34% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.86 | 7.12 | 5.28 | 5.80 | 6.49 | 7.68 | 2.37 | 7.15 | 7.47 | 7.44 | 7.02 | 6.63 | |
| 16.19 | 7.52 | 4.66 | 6.68 | 6.38 | 7.15 | 2.82 | 5.78 | 5.90 | 5.33 | 5.79 | 8.23 | |
| Operating Profit | -0.33 | -0.40 | 0.62 | -0.88 | 0.11 | 0.53 | -0.45 | 1.37 | 1.57 | 2.11 | 1.23 | -1.60 |
| OPM % | -2.08% | -5.62% | 11.74% | -15.17% | 1.69% | 6.90% | -18.99% | 19.16% | 21.02% | 28.36% | 17.52% | -24.13% |
| 0.78 | 0.66 | 0.28 | 0.13 | 0.51 | 0.42 | 0.07 | 0.16 | 0.37 | 0.54 | 0.71 | 2.34 | |
| Interest | 1.41 | 1.09 | 1.33 | 1.28 | 1.08 | 1.38 | 0.83 | 0.71 | 0.25 | 0.14 | 0.02 | 0.03 |
| Depreciation | 0.80 | 0.60 | 0.53 | 0.44 | 0.05 | 0.04 | 0.04 | 0.04 | 0.07 | 0.06 | 0.06 | 0.06 |
| Profit before tax | -1.76 | -1.43 | -0.96 | -2.47 | -0.51 | -0.47 | -1.25 | 0.78 | 1.62 | 2.45 | 1.86 | 0.65 |
| Tax % | -31.82% | -28.67% | -30.21% | -3.24% | 62.75% | 325.53% | -9.60% | 30.77% | 25.93% | 25.31% | 24.73% | -36.92% |
| -1.20 | -1.01 | -0.67 | -2.40 | -0.83 | -2.00 | -1.13 | 0.54 | 1.20 | 1.82 | 1.39 | 0.89 | |
| EPS in Rs | -1.41 | -1.19 | -0.79 | -2.82 | -0.98 | -2.35 | -1.33 | 0.55 | 1.04 | 1.58 | 1.21 | 0.77 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 23% |
| 3 Years: | -4% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 23% |
| 3 Years: | -8% |
| TTM: | -34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 36% |
| 3 Years: | 28% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 9.81 | 11.49 | 11.49 | 11.49 | 11.49 |
| Reserves | 4.12 | 3.10 | 2.48 | 0.15 | -0.68 | -2.68 | -3.79 | 2.94 | 7.87 | 9.67 | 11.06 | 11.93 |
| 18.90 | 16.91 | 12.12 | 12.40 | 11.23 | 11.06 | 11.41 | 9.20 | 1.07 | 0.00 | 0.00 | 0.00 | |
| 3.65 | 1.75 | 1.73 | 2.11 | 1.36 | 1.77 | 1.52 | 1.58 | 0.94 | 1.08 | 2.17 | 1.18 | |
| Total Liabilities | 35.17 | 30.26 | 24.83 | 23.16 | 20.41 | 18.65 | 17.64 | 23.53 | 21.37 | 22.24 | 24.72 | 24.60 |
| 7.28 | 6.69 | 6.36 | 0.62 | 0.57 | 0.53 | 0.49 | 0.44 | 0.43 | 0.49 | 0.43 | 0.39 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 10.71 | 10.71 | 10.13 | 10.02 | 10.07 | 10.07 | 10.07 | 10.07 | 10.03 | 10.03 | 10.03 | 10.03 |
| 17.18 | 12.86 | 8.34 | 12.52 | 9.77 | 8.05 | 7.08 | 13.02 | 10.91 | 11.72 | 14.26 | 14.18 | |
| Total Assets | 35.17 | 30.26 | 24.83 | 23.16 | 20.41 | 18.65 | 17.64 | 23.53 | 21.37 | 22.24 | 24.72 | 24.60 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.09 | 1.78 | 3.67 | 0.64 | 1.68 | 2.20 | 0.47 | -0.36 | -0.28 | 0.08 | 0.28 | -0.72 | |
| -0.08 | 0.00 | 0.34 | 0.12 | 0.03 | -0.01 | 0.00 | 0.00 | 0.14 | 0.30 | -0.19 | 0.57 | |
| 2.33 | -1.98 | -3.78 | -1.00 | -2.25 | -1.55 | -0.48 | 4.59 | -2.92 | -1.21 | -0.02 | -0.03 | |
| Net Cash Flow | 0.17 | -0.20 | 0.23 | -0.24 | -0.55 | 0.64 | -0.01 | 4.23 | -3.07 | -0.83 | 0.06 | -0.18 |
| Free Cash Flow | -2.17 | 1.78 | 3.42 | 0.74 | 1.76 | 2.18 | 0.47 | -0.36 | -0.33 | 0.16 | 0.34 | -0.75 |
| CFO/OP | 612% | -475% | 589% | -32% | 1,464% | 411% | -104% | -26% | -17% | 4% | 24% | 44% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 249.47 | 382.94 | 233.66 | 254.24 | 140.60 | 97.90 | 66.22 | 94.95 | 52.77 | 28.94 | 44.20 | 23.12 |
| Inventory Days | 50.63 | 28.42 | 36.10 | 55.02 | 47.76 | 12.70 | 145.00 | 84.81 | 60.83 | 108.77 | 94.58 | 96.05 |
| Days Payable | 72.93 | 32.86 | 97.60 | 173.11 | 98.93 | 88.07 | 285.00 | 122.38 | 45.10 | 85.81 | 162.49 | 52.83 |
| Cash Conversion Cycle | 227.17 | 378.50 | 172.15 | 136.15 | 89.43 | 22.53 | -73.78 | 57.38 | 68.50 | 51.91 | -23.71 | 66.35 |
| Working Capital Days | 170.99 | 203.52 | -137.57 | 213.97 | 191.22 | -153.03 | -840.89 | -297.10 | 164.67 | 319.87 | 399.32 | 535.11 |
| ROCE % | -1.13% | -1.13% | 1.43% | -4.39% | 2.84% | 5.07% | -2.55% | 7.83% | 8.82% | 12.45% | 8.60% | 3.09% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Work in Progress (CWIP) INR Lakhs |
|
|||||||||||
| Freight & Octroi (Export & Outward) - Standalone INR Lakhs |
||||||||||||
| Number of Permanent Employees Number |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - FY2026 Secretarial Compliance Report notes 1-day shareholding pattern delay, 7-day RTA certificate delay, INR 2,000 fine.
-
Announcement under Regulation 30 (LODR)-Change in Management
28 May - Parnax Lab approved FY26 audited standalone and consolidated results, and reappointed Yogesh K. Varia for five years.
- Results For The Quarter And Year Ended March, 2026 28 May
-
Board Meeting Outcome for Board Meeting Outcome For Consideration And Approval Of Standalone & Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2026, Along With Auditor'S Report Thereon.
28 May - Board approved audited FY26 standalone/consolidated results and reappointed Yogesh K. Varia as independent director for five years.
-
Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Audited IND- AS Compliant Financial Results Along With Auditor Report For The Quarter (Q4) And Year Ended 31St March, 2026
20 May - Board meets May 28, 2026 to approve Q4 and FY26 audited standalone and consolidated results.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
PLL is a part Naxpar Group and is a WHO-approved and EHS-compliant Company. It is into contract manufacturing of Liquid Orals, Capsules, Ointments, External Powders & Tablets with its manufacturing facility located
at Silvassa.